In January this year, Aurobindo shareholders had approved to raise up to USD 350 million through a Qualified Institutional Placement (QIP) but the company did not raise funds due to unfavourable market conditions. The validity of the resolution is for one year.
"Hence, the Board of Directors have considered that a revised approval in modification of the earlier approval be sought from the members for fund raising up to USD 600 million... Through various means of issue of securities like FCCBs and/or ADRs or GDRs and /or QIP, QFIs and/or any other suitable financial instruments," it added.
"The proposed resolution is an enabling resolution authorising the Board of Directors to mobilise adequate resources in one or more tranche or tranches, at such suitable time or times, to meet the growing needs of the company by way of issue of any of the above mentioned securities," it added.
Aurobindo Pharma shares today ended at Rs 815.85 apiece on the BSE, down 1.84 per cent from previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
